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Chronic obstructive pulmonary disease (COPD) is
characterized by progressive and irreversible airflow
limitation caused by abnormal inflammation in the
lungs. Many risks factors are associated with COPD,
but cigarette smoking is by far the most important
one [1–3]; approximately 15% of cigarette smokers
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Cytokine-induced inflammation is the predominant underlying mechanism in chronic obstructive
pulmonary disease (COPD). Genetic factors may play a pivotal role in the development of this
disease. This study looked at the relationship between COPD and genetic polymorphisms in the
genes encoding some of these cytokines in a Taiwanese population. The genetic polymorphisms
examined in this study were tumor necrosis factor (TNF)-a(−308), TNF-a(+ 489), interleukin(IL)-
1b(−31), interleukin-1 receptor antagonist (IL-1 RN), and IL-6(−174). In total, 30 patients with COPD,
64 subjects at risk of COPD and 115 controls were recruited to the study between 1999 and 2003.
DNA was collected from these subjects and analyzed by polymerase chain reaction with sequence-
specific primers and restriction enzyme fragment length polymorphism analysis. The frequencies
of cytokine genotypes in COPD cases and controls, respectively, were as follows: for G/G in TNF-
a(−308), 76.7% and 83.5%; for G/G in TNF-a(+ 489), 76.7% and 68.7%; for C/T in IL-1b(−31),
60.0% and 55.7%; for 4R/4R in IL-1 RN, 80.0% and 86.1%; and for G/G in IL-6(−174), 100.1% and
98.3%. There was no difference in the distribution of the frequencies of these genotypes and alle-
les between COPD cases and controls. Moreover, no association was found between these genetic
polymorphisms in cytokines and COPD (regardless of COPD subtypes) with respect to cigarette
smoking or pulmonary function tests. Despite this, smoking is still an important risk factor for
developing COPD.
Key Words: COPD, interleukin, smoking, tumor necrosis factor
(Kaohsiung J Med Sci 2008;24:126–37)
Cytokine genes and COPD in Taiwan
Kaohsiung J Med Sci March 2008 • Vol 24 • No 3 127
develop COPD [4]. Genetic factors are also thought
to contribute to the pathogenesis in COPD [5,6].
Cytokines are immunoregulatory substances that
are synthesized by macrophages and lymphocytes.
Cytokines are central to the etiology of COPD, as they
can destroy small airways and parenchyma in the
lungs, and therefore impair lung function. Previous
studies have identified the cytokines tumor necrosis
factor (TNF)-α, interleukin (IL)-1β and IL-6 to be in-
volved in the inflammatory process in COPD [7–11].
Many studies have attempted to investigate the effect
of certain cytokine polymorphisms on the risk of devel-
oping COPD [12–23]. Hegab and colleagues showed
that the IL-1b gene may be involved in the pathogen-
esis of COPD in a case-controlled study accounting for
the varied susceptibility across various populations
[14]. Sakao et al found the polymorphism TNF-a(−308)
to be significantly associated with COPD in smokers
[20]. Kucukaycan and colleagues also looked at the
association between various TNF-a gene polymor-
phisms and COPD in different patients, and found 
a positive link with the TNF-a(+ 489) G/A polymor-
phism in patients with COPD without radiologic evi-
dence of emphysema [13]. Results from other studies
have been conflicting [12,15,16,18,19,21,22]. So far,
the relationship between genetic polymorphisms of
cytokines and COPD has been controversial. This may
be due to contributions of multiple genes to COPD,
to interactions between the genotype and environment,
or to variations in the presentation of genetic factors
in COPD between different populations.
Although many studies have been performed else-
where, few have been carried out in Taiwan. In the pres-
ent study, we investigated whether the TNF-a(−308),
TNF-a(+489), IL-1b(−31), IL-1 RN (interleukin-1 receptor
antagonist) and IL-6(−174) polymorphisms are associ-
ated with the development of COPD in a Taiwanese
population sample.
METHODS
Study design
In this multicenter case-controlled study, we enrolled
209 people (30 COPD patients, 64 people at risk of
COPD, and 115 without COPD or risks related to
COPD) between November 1999 and February 2003
from four hospitals (Chung-Ho Memorial Hospital,
Kaohsiung Medical University, Kaohsiung Municipal
Hsiao-Kang Hospital, and Kaohsiung Municipal Union
Hospital) in Kaohsiung, Taiwan. All diagnoses of COPD
were made by pulmonary physicians from the three
internal medicine departments.
The diagnosis of COPD was based on the criteria
established by The National Heart, Lung and Blood
Institute and World Health Organization Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD)
[24]: patients who have smoked or had exposure to
pollutants, have a cough, sputum or dyspnea, have a
family history of respiratory disease, and who have 
a ratio of post-bronchodilator forced expiratory volume
in the first second (FEV1)/forced vital capacity (FVC)
> 0.7 combined with FEV1% predicted ≥ 80% as deter-
mined by spirometric testing are defined as patients at
risk of COPD. Patients with dyspnea, chronic cough,
chronic sputum production and a history of expo-
sure to risk factors (such as tobacco), as well as post-
bronchodilator FEV1/FVC and FEV1% predicted values
determined by spirometry that match the following
criteria of mild (≤ 0.7 and ≥ 80%), moderate (≤ 0.7 and
50–80%), severe (≤ 0.7 and 30–50%), very severe (≤ 0.7
and < 30%) or FEV1 < 50% predicted plus chronic res-
piratory failure were defined as COPD cases. Patients
with chronic asthma, recent upper respiratory infection,
pulmonary tuberculosis, bronchiectasis, pulmonary
neoplasm and α1-antitrypsin deficiency were excluded
from the study. However, patients with mildly calcified
pulmonary parenchyma and chest radiographs that
indicated old pulmonary tuberculosis were included.
One hundred and fifteen controls were enrolled
from the same hospitals (see above); they were free
from COPD and did not have any other systemic dis-
ease or respiratory disease, including asthma, pul-
monary neoplasm, pulmonary tuberculosis or recent
upper respiratory infection. Subjects were matched
to a control by age (within 3 years) and sex.
A pulmonary function test was used to quantify
criteria to classify patients with COPD, persons at
risk of COPD and controls (and groups with different
genetic polymorphisms of cytokines thereof) and not
as an inclusion criteria as such. All controls were
required to produce lung function values of forced
vital capacity (FVC) > 80%, FEV1 > 80%, and FEV1/
FVC > 70%.
This study was approved by the Institutional Review
Board of Kaohsiung Medical University Hospital. We
obtained informed consent from all of the subjects
before they participated in this study.
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Procedure
DNA was extracted from peripheral whole blood using
the PureGene DNA Purification Kit (Gentra Systems,
Minneapolis, MN, USA). Polymerase chain reaction
(PCR) and restriction enzyme fragment length poly-
morphism (RFLP) analysis were used to analyze the
alleles of genetic polymorphisms: guanine (G) or aden-
osine (A) for TNF-a(−308) (TNF-a, GenBank accession
no. X02910) and TNF-a(+489); cytosine (C) or thymine
(T) for IL-1b(−31) (IL-1b(−31), GenBank accession no.
M15330); 4R or 2R forms for IL-1 RN (IL-1 RN,
GenBank accession no. M55646); and G or C for IL-
6(−174) (IL-6(−174), GenBank accession no. M18403).
The length of PCR products, annealing tempera-
ture and cycle numbers used during PCR are listed in
Table 1. The PCR reactions were set up as follows.
• TNF 308: template (100 ng/λ) 3 μL, primer-F
(80pmol/λ) 1μL, primer-R (80pmol/λ) 1μL, dNTP
(2.5 mM) 5μL, 10X PCR buffer 5μL, MgCl2 (25 mM)
0 μL , tag 1 μL, ddH2O 38 μL.
• TNF 489: template (200 ng/λ) 2 μL, primer-F
(10pmol/λ) 3μL, primer-R (10pmol/λ) 3μL, dNTP
(10 mM) 2 μL, 10X PCR buffer 5 μL, MgCl2 (10 mM)
3 μL, tag 1 μL, ddH2O 31 μL.
• IL-1β(−31): template (100 ng/λ) 0.5 μL, primer-F
(20 pmol/λ) 0.5 μL, primer-R (20 pmol/λ) 0.5 μL,
dNTP (1 mM) 2 μL, 10X PCR buffer 2.5 μL, MgCl2
(2.5 nM) 1 μL, tag 0.2 μL, ddH2O 17.8 μL.
• Il-RN: template (100 ng/λ) 0.3 μL, primer-F
(20 pmol/λ) 0.5 μL, primer-R (20 pmol/λ) 0.5 μL,
dNTP (1 mM) 2 μL, 10X PCR buffer 2.5 μL, MgCl2
(2.5 nM) 1 μL, tag 0.2 μL, ddH2O 18 μL.
• IL-6(−174): template (100 ng/λ) 1 μL, primer-F
(20 pmol/λ) 0.5 μL, primer-R (20 pmol/λ) 0.5 μL,
dNTP (1 mM) 0.4 μL, 10X PCR buffer 2.5 μL, MgCl2
(2.5 nM) 0.4 μL, tag 0.2 μL, ddH2O 19.5 μL.
We used a PTC-200 thermocycler (Biocompare Inc.,
South San Francisco, CA, USA) for all PCR reactions
in our study.
The specific PCR products were digested by cor-
responding restriction enzymes and RFLPs were
examined (Table 1). The digested PCR products were
separated in polyacrylamide gels and stained with
ethidium bromide. They were then photographed
under ultraviolet light.
Statistical analysis
Data analysis was performed using SPSS software
(SPSS Inc., Chicago, IL, USA). The χ2 and Fisher’s exact
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Table 2. Demographic characteristics of COPD cases, persons at risk of COPD and controls according to GOLD criteria*
Controls At risk of COPD 
p
COPD 
p
(n = 115) (n = 64) (n = 30)
Sex 0.92 0.16
Male 103 (89.6) 57 (89.1) 24 (80.0)
Female 12 (10.4) 7 (10.9) 6 (20.0)
Educational level 0.04 0.70
Illiterate and elementary school 75 (65.2) 31 (48.4) 21 (70.0)
Junior high school 17 (14.8) 19 (29.7) 5 (16.7)
Senior high school and above 23 (20.0) 14 (21.9) 4 (13.3)
Cigarette smoking† < 0.001 < 0.001
Nonsmoker 72 (62.6) 8 (12.5) 5 (16.7)
≤ 10 cigarettes/d 20 (17.4) 13 (20.3) 10 (33.0)
11–20 cigarettes/d 19 (16.5) 33 (51.6) 9 (30.0)
> 20 cigarettes/d 4 (3.5) 10 (15.6) 6 (20.0)
Alcohol consumption‡ 0.28 0.15
Non-drinking 81 (70.4) 40 (62.5) 17 (56.7)
Drinking 34 (29.6) 24 (37.5) 13 (43.3)
Betel nut chewing§ 0.17 0.09
Non-chewing 102 (88.7) 52 (81.2) 23 (76.7)
Chewing 13 (11.3) 12 (18.8) 7 (23.3)
Age (yr) 65.0 ± 10.5 64.0 ± 12.1 0.82 68.7 ± 10.9 0.23
Pulmonary function test
FVC% 96.3 ± 16.2 80.5 ± 20.0 < 0.001 72.8 ± 39.7 < 0.001
FEV1% 105.2 ± 21.6 85.0 ± 17.4 < 0.001 55.2 ± 25.2 < 0.001
FEV1/FVC% 89.7 ± 13.2 85.3 ± 8.2 0.042 57.6 ± 10.6 < 0.001
*Data are presented as n (%) or mean ± standard deviation; †persons who reported smoking more than 1 cigarette per day for at least
12 months were defined as cigarette smokers; ‡persons who reported drinking beer, wine or distilled spirits more twice per month for
at least 6 months were defined as alcoholic beverage drinkers; §persons who reported regularly chewing betel nut 2 times per week
for at least 6 months were defined as betel nut chewers. COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for
Chronic Obstructive Lung Disease; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second.
tests were used to assess the crude relationship between
COPD and the following variables: demographic char-
acteristics, genetic polymorphisms, and cigarette, alco-
hol and betel nut consumption. The mean age and
pulmonary function test values between the case and
control groups were compared using Student’s t test.
The distributions of all genotypes were examined and
found to obey Hardy-Weinberg laws. Statistical signif-
icance was taken as p < 0.05.
The sex- and age-adjusted odds ratios and corre-
sponding 95% confidence intervals derived from mul-
tiple logistic regression models were used to estimate
the relationship between genetic polymorphisms and
COPD. The baseline genotypes for TNF-a(−308), TNF-
a(+ 489), IL-1b(−31), IL-1 RN and IL-6(−174) poly-
morphisms were G/G, G/G, C/C, 4R/4R and G/G,
respectively.
RESULTS
The demographic characteristics of our study group
are summarized in Table 2. Out of a total of 209 sub-
jects, the average age (68.7 ± 10.9 years) of those with
COPD was similar to that of the group at risk of COPD
(64.0 ± 12.1 years) and the control group (65.0 ± 10.9
years). Cigarette smoking (p < 0.001) was the only
variable that differed significantly between controls,
persons at risk of COPD and those with COPD. Educa-
tional level was different between controls and persons
at risk of COPD. There was no significant variation 
in gender, alcohol consumption or the prevalence of
betel nut chewing across the groups. The mean FVC%,
FEV1% and FEV1/FVC% values in patients with COPD
were 72.8±39.7, 55.2±25.2 and 57.6 ±10.6, respectively;
those in patients at risk of COPD were 80.5 ± 20.0,
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85.0 ± 17.4 and 85.3 ± 8.2, respectively; and those in
controls were 96.3 ± 16.2, 105.2 ± 21.6 and 89.7 ± 13.2,
respectively (Table 2). The lung function values in
patients with COPD were significantly different from
those in controls (p < 0.001).
Table 3 shows the analysis of the genetic polymor-
phisms in our selected cytokines. No significant dif-
ferences in the frequencies of genotypes and alleles for
these polymorphisms at TNF-a(−308), TNF-a(+ 489),
IL-1b(−31), IL-1 RN and IL-6(−174) were identified
among controls, patients at risk of COPD and patients
with COPD (p > 0.05). Furthermore, no significant ge-
netic linkage disequilibrium between any of these ge-
netic polymorphisms was detected (not shown in table).
No significant relationship between chronic bronchitis,
emphysema or mixed type and any of the genetic poly-
morphisms at TNF-a(−308), TNF-a(+ 489), IL-1b(−31),
IL-1 RN and IL-6(−174) was apparent in either of the
different subtypes of COPD or controls (Table 4).
The relationships between the different genotypes
of each genetic polymorphism and COPD in smokers
and nonsmokers were also examined (Table 5). Most
polymorphisms were associated with an increased
risk of developing COPD (p < 0.05), with the exception
of TNF-a(−308) G/G, TNF-a(−308) G/A and A/A, IL-
1b(−31) C/C and IL-1b(−31) T/T in COPD cases.
Finally, the relationships between the genetic poly-
morphisms examined and the results of pulmonary
Table 3. Relationships between polymorphisms at TNF-a(−308), TNF-a(+ 489), IL-1b(−31), IL-1 RN and IL-6(−174) and
COPD cases (according to GOLD criteria), persons at risk of COPD and controls
At risk of COPD COPD cases
Genotypes/alleles Controls, n (%)
n (%) p aOR* (95% CI) n (%) p aOR* (95% CI)
TNF-a(−308)
G/G 96 (83.5) 52 (81.2) 0.66† 1 23 (76.7) 0.48† 1
G/A 18 (15.6) 12 (18.8) 1.25 (0.57–2.79) 6 (20.0) 1.41 (0.52–3.97)
A/A 1 (0.9) 0 (0.0) – 1 (3.3) 4.21 (0.20–70.17)
G allele 210 (91.3) 116 (90.6) 0.83† 1 50 (86.2) 0.24† 1
A allele 20 (8.7) 12 (9.4) 1.08 (0.52–2.29) 8 (13.8) 1.69 (0.71–4.07)
TNF-a(+ 489)
G/G 79 (68.7) 49 (76.6) 0.44† 1 23 (76.7) 0.64† 1
G/A 35 (30.4) 15 (23.4) 0.71 (0.37–1.42) 7 (23.3) 0.71 (0.39–1.81)
A/A 1 (0.9) 0 (0.0) – 0 (0.0) –
G allele 203 (84.6) 113 (88.3) 0.33† 1 53 (88.3) 0.46† 1
A allele 37 (15.4) 15 (11.7) 0.71 (0.37–1.41) 7 (11.7) 0.70 (0.29–1.78)
IL-1b(−31)
C/C 23 (20.0) 15 (23.4) 0.52† 1 6 (20.0) 0.87† 1
C/T 64 (55.7) 38 (59.4) 0.89 (0.41–1.99) 18 (60.0) 1.07 (0.37–3.07)
T/T 28 (24.3) 11 (17.2) 0.59 (0.21–1.60) 6 (20.0) 0.85 (0.21–2.93)
C allele 110 (47.8) 68 (57.6) 0.08† 1 30 (50.0) 0.76† 1
T allele 120 (52.2) 50 (42.4) 0.69 (0.42–1.09) 30 (50.0) 0.91 (0.55–1.68)
IL-1 RN
4R/4R 99 (86.1) 59 (92.2) 0.34† 1 24 (80.0) 0.56† 1
4R/2R 15 (13.0) 4 (6.3) 0.46 (0.17–1.46) 6 (20.0) 1.67 (0.61–4.77)
2R/2R 1 (0.9) 1 (1.5) 1.69 (0.12–28.43) 0 (0.0) –
4R 213 (92.6) 122 (95.3) 0.32† 1 54 (90.0) 0.51† 1
2R 17 (7.4) 6 (4.7) 0.63 (0.27–1.70) 6 (10.0) 1.42 (0.56–3.78)
IL-6(−174)
G/G 113 (98.3) 64 (100.0) – – 30 (100.0) – –
G/C 2 (1.7) 0 (0.0) 0 (0.0)
C/C 0 (0.0) 0 (0.0) 0 (0.0)
G allele 228 (99.1) 128 (100.0) 0.54‡ – 60 (100.0) 1.00‡ –
C allele 2 (0.9) 0 (0.0) 0 (0.0)
*Adjusted for age and sex; †χ2 test; ‡Fisher’s exact test. TNF = tumor necrosis factor; IL = interleukin; IL-1 RN = interleukin-1 receptor
antagonist; COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; 
Aor = adjusted odds ratio; CI = confidence interval; – = cannot be estimated.
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function tests were examined. It was shown that when
FEV1/FVC was less than 70%, it was not associated
with the genotypes of TNF-a(−308), TNF-a(+ 489), IL-
1b(−31) and IL-1 RN. The difference in FEV1 among
polymorphic groups of these genes was not signifi-
cant (p > 0.05). Similar results were found for FVC
(Table 6).
DISCUSSION
This study was designed to assess the association
between COPD and the genetic polymorphisms at
TNF-a(−308), TNF-a(+ 489), IL-1b(−31), IL-1 RN and
IL-6(−174) in a Taiwanese population. We were unable
to identify any relationship between these genetic
Table 5. Relationships between polymorphisms at TNF-a(−308), TNF-a(+ 489), IL-1b(−31), IL-1 RN and IL-6(−174) and
COPD cases (according to GOLD criteria), persons at risk of COPD and controls, on the basis of cigarette smoking
Genotypes of Controls, At risk of COPD COPD cases
polymorphisms n (%) n (%) p aOR* (95% CI) n (%) p aOR* (95% CI)
TNF-a(−308) G/G
Nonsmoker 61 (65.3) 7 (63.6) 1.00† 1 4 (60.9) 0.81‡ 1
Smoker 35 (36.5) 4 (36.4) 19 (39.1) 1.15 (0.46–2.88)
TNF-a(−308) G/A and A/A
Nonsmoker 11 (57.9) 1 (8.3) 0.01† 1 1 (14.3) 0.08† 1
Smoker 8 (42.1) 11 (91.7) 15.32 (1.78–145.57) 6 (85.7) 8.31 (0.81–83.22)
TNF-a(+ 489) G/G
Nonsmoker 48 (60.8) 6 (12.2) < 0.001‡ 1 5 (21.7) < 0.001‡ 1
Smoker 31 (39.2) 43 (87.8) 11.87 (4.67–30.02) 18 (78.3) 5.64 (1.98–17.01)
TNF-a(+489) G/A and A/A
Nonsmoker 24 (66.7) 2 (13.3) < 0.001‡ 1 0 (0.0) 0.002† –
Smoker 12 (33.3) 13 (86.7) 13.24 (2.71–68.12) 7 (100.0)
IL-1b(−31) C/C
Nonsmoker 13 (56.5) 1 (6.7) 0.002‡ 1 1 (16.7) 0.17† 1
Smoker 10 (43.5) 14 (93.3) 18.33 (2.12–163.76) 5 (83.3) 6.62 (0.69–65.28)
IL-1b(−31) C/T
Nonsmoker 39 (60.9) 6 (15.8) < 0.001‡ 1 2 (11.1) < 0.001‡ 1
Smoker 25 (39.1) 32 (84.2) 8.35 (3.32–23.87) 16 (88.9) 12.54 (2.71–58.32)
IL-1b(−31) T/T
Nonsmoker 20 (71.4) 1 (9.1) < 0.001† 1 2 (33.3) 0.15† 1
Smoker 8 (28.6) 10 (90.9) 24.89 (2.68–227–98) 4 (66.7) 5.10 (0.81–32.99)
IL-1 RN 4R/4R
Nonsmoker 60 (60.6) 8 (13.6) < 0.001‡ 1 4 (16.7) < 0.001‡ 1
Smoker 39 (39.4) 51 (86.4) 9.93 (4.12–23.67) 20 (83.3) 7.24 (2.51–25.43)
IL-1 RN 4R/2R and 2R/2R
Nonsmoker 12 (75.0) 0 (0.0) 0.006† – 1 (16.7) 0.02† 1
Smoker 4 (25.0) 5 (100.0) 5 (83.3) 15.11 (1.45–172.01)
IL-6(−174) G/G
Nonsmoker 70 (61.9) 8 (23.5) < 0.001‡ 1 5 (16.7) < 0.001‡ 1
Smoker 43 (38.1) 26 (76.5) 5.45 (2.35–12.89) 25 (83.3) 8.23 (2.99–23.61)
IL-6(−174) G/C and C/C
Nonsmoker 2 (100.0) 0 (0.0) – – 0 (0.0) – –
Smoker 0 (0.0) 0 (0.0) 0 (0.0)
*Adjusted for age and sex; †Fisher’s exact test; ‡χ2 test. TNF = tumor necrosis factor; IL = interleukin; IL-1 RN = interleukin-1 receptor
antagonist; COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; aOR =
adjusted odds ratio; CI = confidence intervals; – = cannot be estimated.
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polymorphisms and the development of COPD (or
subtypes thereof), even though these genetic poly-
morphisms have links to other diseases [8,11–23,25–30].
One possible cause of the negative result might be
that the number of COPD cases in our study was too
small (30 COPD cases). Another is the fact that the
severity of COPD was not especially dominant because
the average value of predicted FEV1% of the COPD
group in this study was 55.2%, which matches the mod-
erate (stage II) GOLD COPD criteria. Thus, the asso-
ciation between COPD and genetic polymorphisms
was not significant in our study.
In addition, we were unable to identify a relation-
ship between these cytokine genetic polymorphisms
and pulmonary function data. In our study, cigarette
smoking was not related to genetic polymorphisms
in these cytokines and COPD, possibly because the
number of COPD cases was too small. COPD is a
multifactorial disease; therefore, it is unlikely that its
complicated etiology can be explained with only a
few such factors. We think that ethnicity plays a role.
Different races may exhibit differing genotype and
allele frequencies for these cytokine polymorphisms
and, therefore, the influence of genetic factors on COPD
may differ according to race. This may explain why
many studies have reported conflicting results. In this
way, the genetic polymorphisms in the studied cyto-
kines may not be related to cigarette smoking in the
Taiwanese population, but this may not hold true in
other races; we can only assume that cigarette smok-
ing has no influence on subjects with these genetic
polymorphisms in Taiwan. Furthermore, these genetic
polymorphisms were not related to the results of pul-
monary function tests in Taiwanese subjects, although
smoking is an important risk factor for developing
COPD.
TNF-α is elevated in bronchoalveolar lavages, bron-
chial biopsies and sputum from patients with COPD,
and is known to increase tracheal muscle prolifera-
tion and alter smooth muscle function [20]. The TNF-a
gene is located within the highly polymorphic major
histocompatibility complex (MHC) Class III region of
chromosome 6p21.3. Therefore, TNF-a(−308) may be in
a state of linkage disequilibrium with other diseases
[31]. A previous study suggests that homozygosity
for the TNF-a(−308) A allele predisposes individuals
to more severe airflow obstruction and a worse prog-
nosis in COPD [23]. Huang and colleagues [19] found
that TNF-α plays an important role in the etiology 
of chronic bronchitis in a northern Taiwanese popu-
lation. In their study, carriage of the TNF-a(−308) A
allele was associated with an increased risk of devel-
oping chronic bronchitis, and the percentage of indi-
viduals with a TNF-a(−308) G/A genotype in COPD
and control groups were 33.3% and 4.8%, respectively.
Sakao and colleagues [20] also found a significant
association between a TNF-a(−308) G/A genotype and
smoking-related COPD. They reported that in patients
with COPD, both smokers/ex-smokers and control
groups had different frequencies of TNF-a(−308) alle-
les; besides, 27.1% of their patients had COPD and
9.1% of their controls had the genotype TNF-a(−308)
G/A. The difference in the disturbance of TNF-a(−308)
between our study and those of Huang et al’s and
Sakao et al’s might be due to differences in the cases
studied; approximately one-third of the patients were
nonsmokers in Huang et al’s study (compared to
13.8% in our study) and the patients in Sakao et al’s
study were all smoking-related COPD patients.
The TNF-a(+ 489) polymorphism has also been
associated with other diseases [26–28]. Kucukaycan
and colleagues [13] found an association between 
a TNF-a(+ 489) G/A genotype and COPD in Dutch
Caucasians. In their study, the percentages of subjects
with the TNF-a(+ 489) G/A genotype in the COPD
and control groups were 24% and 14%, respectively.
However, only 3% of their COPD patients were non-
smokers, with no data available on the controls. In
addition, their study was also unable to confirm the
possible cause of an association between TNF-a(+489)
and COPD. Except constituent cases different from
Kucukaycan et al’s study, another possible cause of
TNF-a(+ 489) not being related to COPD in our study
might be that previous studies have shown that the
TNF-a(+ 489) G/A polymorphism does not influence
TNF-a pre-mRNA yielding [27] or TNF-α production
[28]; this could be because the polymorphism itself is
unrelated to the disease, or because no linkage dise-
quilibrium exists between this locus and a nearby
gene or a set of genes related to the disease.
IL-1β is thought to be an important cytokine in-
volved in the irreversible damage of airways [7,18],
and increased amounts of IL-1β have been found in
the sputum of patients with COPD [11]. The IL-1b(−31)
T/C polymorphism is located in a TATA box in the
promoter region and influences the transcriptional
activity of the IL-1b gene [32]. Hegab et al [14]
reported higher incidences of the IL-1b(−31) T/C
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genotype among Japanese patients with COPD (59%)
and control groups (52%) compared with Egyptian
men with or without COPD (43% vs. 41%). Moreover,
Hegab et al found that there was linkage disequilib-
rium between IL-1b(−31) and IL-1 RN, and that there
was no association between IL-1b(−31) and the devel-
opment of COPD. Like Hegab et al’s study, we did
not find IL-1b(−31) T/C to be distributed differently
between patients with COPD and the control group
(60.0% and 55.7%, respectively). However, in contrast
to their study, we did not find linkage disequilibrium
between IL-1b(−31) and IL-1 RN. We think that the
relationship between the polymorphism at IL-1b(−31)
and development of COPD is not so dominant, and
that it should be further examined.
IL-1 receptor antagonist (IL-1 RN) inhibits the
binding of IL-1α and IL-1β to the IL-1 receptor. As a
result of this, the physical, pathologic and inflamma-
tory effects of the cytokine are neutralized [18]. Ishii
and colleagues [18] did not identify an association
between the genetic polymorphisms of IL-1 RN and
individual susceptibility to COPD in a Japanese pop-
ulation. They could not identify any differences in the
frequencies of the different IL-1 RN genotypes 1/1,
1/2, 2/2, and 1/3 (4R/4R, 4R/2R, 2R/2R, 4R/5R)
between patients with COPD and controls. The fre-
quencies of these genotypes were also similar across
the two groups. Hegab et al [14] also reported a simi-
larity between the IL-1 RN allele 1/1, 1/2, 2/2 and
1/3 (4R/4R, 4R/2R, 2R/2R and 4R/5R) in patients
with COPD and controls in Japanese and Egyptian
patients, and a similar distribution of IL-1 RN geno-
types among COPD cases and the control group was
noted in our study. Furthermore, the frequencies of
IL-1 RN genotypes (4R/4R, 4R/2R, 2R/2R) differed
from those in the previously reported Japanese and
Egyptian groups; thus, we think that IL-1 RN is unlikely
to be associated with the pathogenesis of COPD.
IL-6(−174) is located in the 5’ flanking region, the
transcription start site, of the IL-6 gene [33]. This gene
adjusts the presentation of other genes, and it has been
previously linked to various other diseases [25,29,30].
Seifart and colleagues [22] looked at the relationship
between the polymorphism at IL-6(−174) and COPD
in Germany, and found that the distribution of the 
IL-6(−174) alleles in patients with COPD did not dif-
fer from that in their control group. In their study, the
proportions of individuals with G/G, G/C and C/C
genotypes in the COPD group were 36.3%, 46.0% and
17.7%, respectively, and those in the control group
were 43.8%, 45.5% and 10.7%, respectively. Although
the IL-6(−174) alleles were distributed similarly across
patients with COPD and controls (Table 3), the per-
centage of the IL-6(−174) alleles varied; this is a very
different finding to that of Seifart and colleagues, whose
patients all had a G/G genotype. Given that there are
only a limited number of studies on the relationship
between the polymorphism at IL-6(−174) and COPD,
further studies are needed to clarify this relationship.
In conclusion, we did not find any association
between genetic polymorphisms at TNF-a(−308), TNF-
a(+489), IL-1b(−31), IL-6(−174) or IL-1 RN and COPD
or its subtypes in our Taiwan population. Moreover,
we did not find an association between these poly-
morphisms and pulmonary function data in smokers
with COPD. Therefore, we propose that, in Taiwan,
cigarette smoking is the main risk factor for developing
COPD. We suggest that other cytokine polymorphisms
that may also contribute to the risk for COPD should
be examined further.
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